SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $807.54 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $471.59K, a 1.29% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $335.95K, a 322.49% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$453.30K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $331.20K, a 66.33% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $422.99K, a 34.82% increase from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $313.74K, a 88.87% increase from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $166.12K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$382.88K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $471.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $807.54K 10-Q · filed 2026-09-24 | $354.24K derived: sum of 3 quarters · filed 2026-09-24 | $685.44K derived: sum of 4 quarters · filed 2026-09-24 |
| 2026-03-31 | $335.95K 10-Q · filed 2026-05-15 | -$117.35K derived: sum of 2 quarters · filed 2026-05-15 | $213.85K derived: sum of 3 quarters · filed 2026-05-15 | $679.43K derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-12-31 | -$453.30K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$122.11K derived: sum of 2 quarters · filed 2026-03-31 | $343.48K derived: sum of 3 quarters · filed 2026-09-24 | $422.99K 10-K · filed 2026-03-31 |
| 2025-09-30 | $331.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $796.78K derived: sum of 2 quarters · filed 2026-09-24 | $876.30K 10-Q · filed 2025-11-13 | $124.45K derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-06-30 | $465.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | $545.10K 10-Q · filed 2026-09-24 | -$206.74K derived: sum of 3 quarters · filed 2026-09-24 | $776.81K derived: sum of 4 quarters · filed 2026-09-24 |
| 2025-03-31 | $79.52K 10-Q · filed 2026-05-15 | -$672.33K derived: sum of 2 quarters · filed 2026-05-15 | $311.23K derived: sum of 3 quarters · filed 2026-05-15 | $370.10K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$751.84K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $231.71K derived: sum of 2 quarters · filed 2026-03-31 | $290.58K derived: sum of 3 quarters · filed 2026-03-31 | $313.74K 10-K · filed 2026-03-31 |
| 2024-09-30 | $983.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.04M derived: sum of 2 quarters · filed 2025-11-13 | $1.07M 10-Q · filed 2025-11-13 | $1.17M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $58.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $82.03K 10-Q · filed 2025-08-13 | $184.89K derived: sum of 3 quarters · filed 2025-08-13 | $276.15K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $23.16K 10-Q · filed 2025-05-08 | $126.02K derived: sum of 2 quarters · filed 2025-05-08 | $217.28K derived: sum of 3 quarters · filed 2025-05-08 | -$141.45K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $102.86K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $194.12K derived: sum of 2 quarters · filed 2025-02-26 | -$164.61K derived: sum of 3 quarters · filed 2025-02-26 | $166.12K 10-K · filed 2025-02-26 |
| 2023-09-30 | $91.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$267.47K derived: sum of 2 quarters · filed 2024-11-13 | $63.26K 10-Q · filed 2024-11-13 | $72.85K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$358.73K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | -$28.00K 10-Q · filed 2024-09-04 | -$18.41K derived: sum of 3 quarters · filed 2024-09-04 | -$98.36K derived: sum of 4 quarters · filed 2024-09-04 |
| 2023-03-31 | $330.73K 10-Q/A · filed 2024-09-04 | $340.32K derived: sum of 2 quarters · filed 2024-09-04 | $260.38K derived: sum of 3 quarters · filed 2024-09-04 | $84.97K derived: sum of 4 quarters · filed 2024-09-04 |
| 2022-12-31 | $9.59K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | -$70.35K derived: sum of 2 quarters · filed 2024-09-04 | -$245.76K derived: sum of 3 quarters · filed 2024-09-04 | -$382.88K 10-K/A · filed 2024-09-04 |
| 2022-09-30 | -$79.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$255.36K derived: sum of 2 quarters · filed 2023-11-13 | -$392.47K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | -$175.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$312.53K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$137.12K 10-Q · filed 2023-05-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |